BioXcel Therapeutics (BTAI) EPS (Basic) (2017 - 2026)
BioXcel Therapeutics (BTAI) posted EPS (Basic) of -$0.47 for Q2 2026, up 21.61% on a QoQ basis from -$0.6 in Q1 2026, and up 81.32% year-over-year from -$0.26 in Q2 2025.
Powered by 
Analysis
BioXcel Therapeutics (BTAI) EPS (Basic) (2017 - 2026) Analysis & Trends
BioXcel Therapeutics has reported EPS (Basic) for 10 years, with the latest figure at -$0.47 in Q2 2026.
- On a quarterly basis, EPS (Basic) rose 81.32% year-over-year to -$0.47 in Q2 2026; TTM through Jun 2026 was -$2.02, a 76.08% increase from a year earlier, with the FY2025 full-year figure at -$5.44, up 82.72% from the prior year.
- EPS (Basic) was -$0.47 for Q2 2026 at BioXcel Therapeutics, up from -$0.6 in the prior quarter.
- The five-year high for EPS (Basic) was -$0.47 in Q2 2026, with the low at -$31.03 in Q4 2022.
- Average EPS (Basic) over 5 years is -$13.16, with a median of -$10.18 recorded in 2024.
- The sharpest annual moves came in 2022 and 2025: EPS (Basic) sank 96.02% in 2022, then jumped 81.44% in 2025.
- Over 5 years, EPS (Basic) stood at -$31.03 in 2022, then jumped by 60.41% to -$12.28 in 2023, then soared by 54.54% to -$5.58 in 2024, then jumped by 78.94% to -$1.18 in 2025, then soared by 59.82% to -$0.47 in 2026.
- The last three EPS (Basic) figures came in at -$0.47 (Q2 2026), -$0.6 (Q1 2026), and -$1.18 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn | -0.40 |
| 10 | BioXcel Therapeutics | 2.19 Mn | 2.19 Mn | 160,000.00 | -0.47 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.47 |
| Mar 31, 2026 | -0.60 |
| Dec 31, 2025 | -1.18 |
| Sep 30, 2025 | -1.29 |
| Jun 30, 2025 | -2.53 |
| Mar 31, 2025 | -2.86 |
| Dec 31, 2024 | -5.58 |
| Sep 30, 2024 | -6.97 |
| Jun 30, 2024 | -8.08 |
| Mar 31, 2024 | -13.90 |
| Dec 31, 2023 | -12.28 |
| Sep 30, 2023 | -27.60 |
| Jun 30, 2023 | -29.63 |
| Mar 31, 2023 | -29.38 |
| Dec 31, 2022 | -31.03 |
| Sep 30, 2022 | -23.91 |
| Jun 30, 2022 | -21.53 |
| Mar 31, 2022 | -18.00 |
| Dec 31, 2021 | -15.83 |
| Sep 30, 2021 | -15.34 |